Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourLeaning Bearish
15 minBearish
5 minStrong Bullish
Daily trend turns up above $8.60
Key levels
Resistance$9.30
Resistance$8.22
Support$7.15
Support$6.35
Latest news & SEC filings
ProductImmunic Discloses Data From CALLIPER Study, Outlines Next Steps
All IMUX news →Immunic is a clinical-stage biotechnology company creating orally taken, small-molecule medicines aimed at nervous system and digestive tract conditions. Its most advanced candidate, vidofludimus calcium, is in late-stage testing for multiple sclerosis, while IMU-856 is designed to help rebuild the gut lining in illnesses such as celiac disease and inflammatory bowel disease. An earlier program targets additional neurological, digestive and immune-related conditions. The company is headquartered in New York and carries out operations in Germany and Australia.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$2.50
SEPT Mid Target
$27.00
SEPT High Target
$45.00
Analyst Consensus
$27.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMUX.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
PEG, Analyst Consensus
Fair Value
$13.55
0
Moat Score
NONE
1/9
Piotroski Score
-27.7
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
38%
FCF Growth YoY
-1.1%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for IMUX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:17:09 | $8.31 | 6,000 | $$50K | SELL |
| 16:15:20 | $8.34 | 10,000 | $$83K | SELL |
| 16:11:58 | $8.37 | 1,300 | $$11K | BUY |
| 15:38:50 | $8.29 | 1,150 | $$10K | MIDPOINT |
| 15:08:37 | $8.20 | 1,000 | $$8K | MIDPOINT |
5 dark pool trades shown · $$162K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for IMMUNIC, INC. (IMUX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IMMUNIC, INC. (IMUX) is at $7.83, down 3.57% (-$0.29) at the Nov 12, 2026 close.
Latest IMUX news — Nov 6, 2026: Immunic Discloses Data From CALLIPER Study, Outlines Next Steps
The average analyst price target for IMUX is $27.00, ranging from $3 to $45, based on 5 analysts.
Analyst ratings for IMUX: 4 Buy, 5 Hold, 0 Sell — consensus Hold.
IMUX last reported on Aug 11, 2026: EPS -$0.80 vs -$1.16 expected — a beat of 31.0%.
IMUX trades at a P/E of 3.7 vs a Healthcare average of 17.7.
IMUX does not currently pay a dividend.
Support: $7.15, $6.35, $5.06. Resistance: $8.22, $9.30, $10.03.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 6, 2026: Immunic Discloses Data From CALLIPER Study, Outlines Next Steps